论文部分内容阅读
目的探讨标准化特异性免疫治疗儿童过敏性哮喘临床疗效,治疗进程中的不良反应及临床意义。方法对41例临床诊断为儿童过敏性哮喘患儿应用标准化屋尘螨提取液皮下注射进行特异性免疫治疗,观察每次免疫注射后全身及局部不良反应的发生情况。结果 41例患儿中14.64%有不同程度的局部不良反应,24.39%有不同程度的全身不良反应,全身不良反应主要发生在注射维持剂量阶段。而治疗前后患儿肺功能有所改善。结论屋尘螨特异性免疫治疗对过敏性儿童哮喘的治疗耐受性、安全性好,该治疗对缓解患儿临床症状及改善肺功能有良好意义。
Objective To investigate the clinical efficacy of standardized immunotherapy in children with allergic asthma, the adverse reactions in the course of treatment and its clinical significance. Methods 41 cases of children with clinically diagnosed as allergic asthma in children with standardized house dust mite extract subcutaneous injection of specific immunotherapy to observe the incidence of systemic and local adverse reactions after each immunization. Results Of the 41 cases, 14.64% had local adverse reactions in varying degrees and 24.39% had various degrees of systemic adverse reactions. The systemic adverse reactions mainly occurred during the injection and maintenance dose phases. Before and after treatment in children with pulmonary function improved. Conclusion House dust mite-specific immunotherapy is safe and effective for the treatment of allergic asthma in children. The treatment is good for alleviating clinical symptoms and improving pulmonary function in children.